CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • October 28th, 2014 • Daiichi Sankyo Company, LTD • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September [ ], 2014 (this “Agreement”), is entered into by and between Daiichi Sankyo Company, Limited, a Japanese corporation with its principal office at 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan (“Parent”), and Broadridge Corporate Issuer Solutions, Inc., a Pennsylvania corporation, as Rights Agent (together with Parent, the “Parties”).
Sales Agreement for EVISTA® Reached in EuropeSales Agreement • July 14th, 2006 • Daiichi Sankyo Company, LTD • Pharmaceutical preparations
Tokyo, July 14, 2006 – DAIICHI SANKYO EUROPE GmbH (Headquarters: Munich, Germany), the European subsidiary of DAIICHI SANKYO’s wholly-owned subsidiary, Sankyo Co., Ltd. (President: Yasuhiro Ikegami; hereafter Sankyo), and Eli Lilly and Company have signed a marketing and distribution agreement for EVISTA® (raloxifene), an osteoporosis drug, in certain European countries (Germany, Italy, Belgium, Netherlands, Austria, and Switzerland).
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • October 10th, 2014 • Daiichi Sankyo Company, LTD • Pharmaceutical preparations • Delaware
THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of July 31, 2014 (the “Effective Date”) between AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (“Ambit”) and DAIICHI SANKYO, INC., a Delaware Corporation (“Daiichi Sankyo’’).
The Termination of the Contract concerning OTC MedicineTermination Agreement • September 21st, 2006 • Daiichi Sankyo Company, LTD • Pharmaceutical preparations
Novartis Pharma K. K. (head office in Minato-ku, Tokyo: Nobuyuki Baba, President) and Sankyo Co., Ltd. (head office in Chuo-ku, Tokyo: Yasuhiro Ikegami, President) which is the affiliate of Daiichi Sankyo Co., Ltd. (head office in Chuo-ku, Tokyo: Takashi Shoda, President) have agreed to terminate the agreement concluded in January 2004 concerning Lamisil and Nicotinell TTS at the end of December, 2006.
